Evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing total knee replacement
The purpose of this study is to evaluate the efficacy, tolerability, safety, and pharmacokinetics of 4975 in patients undergoing primary unilateral total knee arthroplasty
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Enrollment
214
Direct instillation into the surgical site
Direct instillation into the surgical site
Direct instillation into the surgical site
Numerical Rating Scale (NRS) measures of pain at prespecified times
Time frame: Primary endpoint is 2 days (4-48 hours)
Other efficacy parameters, safety and tolerability of 4975
Time frame: 42 Days or Early Termination
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Alabama Clinical Therapeutics, LLC
Birmingham, Alabama, United States
Springhill Medical Center
Mobile, Alabama, United States
Hellen Keller Hospital
Sheffield, Alabama, United States
Visions Clinical Research/Tucson Medical Center
Tucson, Arizona, United States
Glendale Adventist Medical Center - Lotus Clinical Research
Glendale, California, United States
Physicians Clinical Research Corporation
Laguna Hills, California, United States
Saddleback Memorial Medical Center/Accurate Clinical Trials
Laguna Hills, California, United States
Webster Orthopeadic Medical Group
Oakland, California, United States
UCSF-Mt. Zion Medical Center
San Francisco, California, United States
Orthopedic Associates of Hartford
Hartford, Connecticut, United States
...and 15 more locations